

References

L-32

1. Zahir S, Binesh F, Fariba S, Paknejad H. Study the level of ASCA and panca antibodies in inflammatory bowel diseases in comparison with biopsy findings. *World Journal of Medical Sciences*. 2012;7(2):72-76.
2. Kuna A. Serological markers of inflammatory bowel disease. *Biochem Med (Zagreb)*. 2013;23(1):28-42.
3. Kaul A, Hutfless S, Liu L, et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: A systematic review and meta-analysis. *Inflamm Bowel Dis*. 2012;18(10):1872-1884.
4. ClinicalTrials.gov. U.S. National Institutes of Health. Serologic markers for inflammatory bowel disease during clinical forms with weak or strong evolution capacities. ClinicalTrials.gov Identifier:NCT01216514.
5. Plevy S, Silverberg M, Lockton S, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. *Inflamm Bowel Dis*. 2013;19(6):1139-1148.
6. Cury DB, Mizsputen SJ, Versolato C, et al. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. *Cell Immunol*. 2013;282(1):66-70.
7. Manz M, Burri EM, Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. *BMC Gastroenterol*. 2012;12:5.
8. Moniuszko AN, Wisniewska A, Rydezewska G. Biomarkers in management of inflammatory bowel disease. *Prz Gastroenterol*. 2013; 8(5):275-283.
9. Henderson P, Casey A, Lawrence S, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. *Am J Gastroenterol* 2012;107:941–949.
10. Bhullar M, Macrae F, Brown G, et al. Prediction of Crohn's disease aggression through NOD2/CARD15 gene sequencing in an Australian cohort. *World J Gastroenterol* 2014;20(17):5008–5016.
11. Naser S, Arce M, Khaja A, et al. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. *World J Gastroenterol*. 2012;18(5) 412–424.
12. McGovern D, Melmed G. Crohn Disease and NOD2/CARD15. *Medscape*. 2013;November. Accessed March 12, 2015.
13. Vaos G, Kostakis I, Zavras N, et al. The role of calprotectin in pediatric disease. *Biomed Res Int*. 2013; 2013:542363.
14. Smith L, Gaya D. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. *World J Gastroenterol*. 2012;18(46):6782–6789.
15. Holtman G, Lisman-vanLeeuwen, Kollen B, et al. Challenges in diagnostic accuracy studies in primary care: The fecal calprotectin example. *BMC Fam Pract*. 2013;14:179.
15. Walsham N, Sherwood R. Fecal calprotectin in inflammatory bowel disease. *Clin Exp Gastroenterol*. 2016;9:21–29.

16. Menees S, Powell C, Kurlander J, et al. A meta-analysis of the utility of c-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *The American Journal of Gastroenterology*. 2015;110:444-454.
17. Chey W, Kurlander J, et al. Irritable bowel syndrome: A clinical review. *JAMA*. 2015;313(9):949-958.